abstract |
PCT No. PCT/EP93/02488 Sec. 371 Date Mar. 15, 1995 Sec. 102(e) Date Mar. 15, 1995 PCT Filed Sep. 14, 1993 PCT Pub. No. WO94/06761 PCT Pub. Date Mar. 31, 1994Compounds of formula (I) wherein R1, R2, R3 and R4 are each H or C1-C4 alkyl; R5 is (CH2)mNHSO2R6 or (CH)mNHCOR6; R6 is C1-C6 alkyl, C3-C6 cycloalkyl optionally substituted by aryl, aryl or heteroaryl; R7 is H, C1-C4 alkyl, C1-C4 alkoxy, halo, CF3, OCF3, CN, CONH2, or S(O)n(C1-C4 alkyl); X is CH2, CHCH3, CH(OH), C(OH)CH3, C=CH2, CO or O; m is 0 or 1 and n is 0, 1 or 2, and their pharmaceutically acceptable salts and biolabile esters, are antagonists of thromboxane A2 of utility, particulary in combination with a thromboxane synthetase inhibitor, in the treatment of atherosclerosis and unstable angina and for prevention of reocclusion after percutaneous transluminal angioplasty. |